Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Riding High, Victoza Hopes To Gain Ground Over Popular DPP-4s With Label Change

Executive Summary

FDA label now notes superior efficacy and greater weight loss for Novo Nordisk’s injectable GLP-1 receptor agonist Victoza vs. Mercks’ DPP-4 inhibitor Januvia. Superiority would be expected for a GLP-1, but label still has potential to encourage earlier use of the class.

You may also be interested in...



Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch

Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.

Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy

Sanofi and Lilly, latecomers to the rising class of GLP-1 diabetes drugs, may not have much to differentiate their drugs from other offerings. But at investor forums at the American Diabetes Association meeting, they highlighted some possibilities, including hypertension data and combination therapies.

Alogliptin Rejection Dents Takeda’s Diabetes Franchise

Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS054380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel